Choose Your News
Loading...
Tags:
Thumbnail
Because it pretty much went against 30 years of previous government policy toward the corporate sector, Sir Vince Cable's intervention in 2014 to prevent Astrazeneca... [Read More]
Thumbnail
An investor in Boulder-based Array BioPharma on Thursday filed a lawsuit against the company alleging it failed to provide shareholders key information surrounding its financial... [Read More]
Photo Illustration by Elizabeth Brockway/The Daily Beast Viagra burst onto the market and into pop culture in 1998. The little blue pill's approval by the... [Read More]
Thumbnail
New York The major U.S. stock indexes closed at record highs on Friday, with the S&P 500 ending above 3,000 for the... [Read More]
Thumbnail
Pfizer's recent PPMD conference revealed very concerning safety issues with its gene therapy candidate for DMD. Pfizer's candidate might be headed down Solid Bi... [Read More]
Thumbnail
Trader Dan Nathan on whether it's time to fade Pfizer, as the company gets slammed. [Read More]
Thumbnail
In this episode of Entrepreneur Network partner Jason Saltzman's Resilience  series, we hear from Andrew Myers, the founder of RippleMatch, an organization that helps college... [Read More]
Thumbnail
The Cambridge, Mass.-based company, which is focused on therapies known as RNA interference for genetically defined diseases, on Thursday appointed Jeff Poulton to succeed current... [Read More]
As of the most recently reported period, short sellers favored Pfizer, Intel and Microsoft above all other Dow stocks. [Read More]
European Union antitrust authorities conditionally approved late Wednesday the acquisition by GlaxoSmithKline PLC (GSK.LN) of Pfizer Inc.'s PFE consumer... [Read More]
Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District Court for the District of Delaware on... [Read More]
T-Mobile, Tesla, Marriott, GlaxoSmithKline, Pfizer and Caliva are the companies to watch. [Read More]
GlaxoSmithKline PLC (GSK.LN) said Wednesday that ViiV Healthcare, its HIV venture with Pfizer Inc. (PFE), has met primary endpoint in a phase 3 clinical... [Read More]
Sarepta Therapeutics had seen its stock surge after preliminary safety and efficacy data from Pfizer came about for its gene therapy tech, which was observed... [Read More]
Loading...
Preview